Research Triangle Park, NC, September 24, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has appointed Jodi A. Cook, PhD to its board of directors. […]
Read More… from FENNEC APPOINTS JODI A. COOK, PhD TO ITS BOARD OF DIRECTORS
Seasoned commercial leader to lead the anticipated launch of PEDMARKTM Research Triangle Park, NC, September 9, 2019 – Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARKTM (a unique formulation of sodium thiosulfate (STS)) for the prevention of platinum-induced ototoxicity in pediatric patients, today announced that it has […]
Read More… from FENNEC APPOINTS SHUBH GOEL AS CHIEF COMMERCIAL OFFICER
Anticipate PEDMARK™ New Drug Application (NDA) completion by early 2020 Strong financial position with $17.5 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., Aug. 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty pharmaceutical company focused on the development of PEDMARK™ (a unique formulation of sodium thiosulfate (STS)) for the prevention […]
Read More… from Fennec Provides Business Update and Announces Second Quarter 2019 Financial Results
Research Triangle Park, NC — (Marketwired) – June 18, 2019 – Fennec Pharmaceuticals Inc. (the “Company”) (NASDAQ:FENC) (TSX:FRX) today announced that the nominees listed in the management proxy circular dated May 14, 2019 (the “Circular”) for the Annual General and Special Meeting of Shareholders were elected as directors of the Company at the Annual General […]
Fennec Provides Business Update and Announces First Quarter 2019 Financial Results Targeting New Drug Application to U.S. FDA for PEDMARKTM in late 2019 to early 2020 Strong financial position with $20.2 million in cash and no debt RESEARCH TRIANGLE PARK, N.C., May 09, 2019 (GLOBE NEWSWIRE) — Fennec Pharmaceuticals Inc. (NASDAQ:FENC; TSX: FRX), a specialty […]
Read More… from Fennec Provides Business Update and Announces First Quarter 2019 Financial Results